Physician profile
Li Jiang
NPI 1720345416
$3,568.91
in general payments reported to CMS, 2019-2025
19 companies · $561 in 2025
The $561 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,846 · 2020: $169 · 2021: $82.39 · 2022: $61.87 · 2023: $375 · 2024: $474 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,094.67 | 2019-2025 | |
| Amgen INC. | $658.73 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Pfizer INC. | $304.32 | 2019-2025 | |
| Genentech USA, INC. | $293.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $251.25 | 2019-2024 | Benlysta |
| Ucb, INC. | $196.73 | 2019-2023 | Cimzia |
| Genzyme Corporation | $117.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $110.23 | 2019-2024 | Orencia |
| Janssen Biotech, INC. | $98.54 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $75.53 | 2019-2025 | |
| Celgene Corporation | $67.43 | 2019 | |
| Antares Pharma, INC. | $59.32 | 2019 | |
| Lilly USA, LLC | $50.25 | 2019-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.08 | 2023-2024 | Cyltezo |
| Sobi, INC | $44.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $42.74 | 2024 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals, LTD. | $25.15 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $15.22 | 2025 | Saphnelo |
| Ultragenyx Pharmaceutical INC. | $14.42 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.